{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:13:11Z","timestamp":1794971591557,"version":"4.9.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Amphotericin B deoxycholate (AmB-D) is standard of care treatment for neonatal invasive candidiasis (IC). Micafungin (MCA) has broad-spectrum fungicidal activity against <jats:italic toggle=\"yes\">Candida<\/jats:italic> spp. We compared the efficacy and safety of intravenous MCA with intravenous AmB-D and assessed the pharmacokinetics of MCA in infants &gt;2\u2013120 days of age with proven IC in a phase 3, randomized, double-blind, multicenter, parallel-group, noninferiority study (NCT00815516).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Infants were randomized 2:1 to MCA (10\u2009mg\/kg\/d) or AmB-D (1\u2009mg\/kg\/d) for \u226521 days. Primary efficacy endpoint was fungal-free survival (FFS) 1 week after last study drug dose. MCA population pharmacokinetics included simulated area under the curve (AUC) at steady state and maximum plasma concentration after 2-hour infusion. AUC pharmacodynamic target exposure was 170 \u00b5g\u00b7h\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirty infants received MCA (n = 20) or AmB-D (n = 10). The trial was terminated early because of slow recruitment. FFS was observed in 12 of 20 [60%; 95% confidence interval (CI): 36%\u201381%] MCA-group infants and in 7 of 10 (70%; 95% CI: 35%\u201393%) AmB-D-group infants. The most common treatment-emergent adverse events were anemia [MCA: n = 9 (45%); AmB-D: n = 3 (30%)] and thrombocytopenia [n = 2 (10%) and n = 3 (30%), respectively]. Model-derived mean AUC at steady state for MCA was 399.3\u2009\u00b1\u2009163.9 \u00b5g\u00b7h\/mL (95% prediction interval: 190.3\u2013742.3 \u00b5g\/mL); steady state and maximum plasma concentration after 2-hour infusion was 31.1\u2009\u00b1\u200910.5 \u00b5g\/mL (95% prediction interval: 17.0\u201349.7 \u00b5g\/mL). MCA exposures were above the AUC pharmacodynamic target exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Within the study limitations, infants with IC treated with MCA achieved similar FFS compared with AmB-D. Both agents were safe and well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001996","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T03:16:53Z","timestamp":1522293413000},"page":"992-998","source":"Crossref","is-referenced-by-count":44,"title":["A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis"],"prefix":"10.1097","volume":"37","author":[{"given":"Daniel K.","family":"Benjamin","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, University of Virginia Health System, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Orange County, Orange County, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manzoni","sequence":"additional","affiliation":[{"name":"Neonatology and NICU, Azienda Ospedaliera OIRM\u2013Sant\u2019Anna Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Kovanda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lademacher","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Jednachowski","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhang","family":"Wu","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc., Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Kaibara","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Internal Medicine\/Infectious Disease, Weill Cornell Medicine of Cornell University, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/1471-2334-14-327","article-title":"Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls.","volume":"14","author":"Barton","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/INF.0b013e3182467a72","article-title":"Antifungal therapy and outcomes in infants with invasive Candida infections.","volume":"31","author":"Ascher","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"3, pt 1","key":"R3-20230912","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1542\/peds.112.3.634","article-title":"Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques.","volume":"112","author":"Benjamin","year":"2003","journal-title":"Pediatrics"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jpeds.2013.04.034","article-title":"Neurodevelopmental outcome of extremely low birth weight infants with Candida infection.","volume":"163","author":"Adams-Chapman","year":"2013","journal-title":"J Pediatr"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/00006454-200009000-00003","article-title":"Persistently positive cultures and outcome in invasive neonatal candidiasis.","volume":"19","author":"Chapman","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 7","key":"R6-20230912","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/14656566.2015.1031108","article-title":"Advances in the treatment of invasive neonatal candidiasis.","volume":"16","author":"Botero-Calderon","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1136\/archdischild-2012-303350","article-title":"Update on the management of Candida infections in preterm neonates.","volume":"100","author":"Manzoni","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/INF.0000000000000299","article-title":"Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.","volume":"33","author":"Bes","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00148581-200709050-00004","article-title":"Antifungal agents in neonates: issues and recommendations.","volume":"9","author":"Almirante","year":"2007","journal-title":"Paediatr Drugs"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40265-014-0227-3","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.","volume":"74","author":"Autmizguine","year":"2014","journal-title":"Drugs"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/myc.12209","article-title":"An investigation of Candida species isolated from blood cultures during 17 years in a university hospital.","volume":"57","author":"Kazak","year":"2014","journal-title":"Mycoses"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/INF.0b013e31819f1f50","article-title":"Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.","volume":"28","author":"Wade","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20230912","first-page":"77","article-title":"Colonization and antifungals susceptibility patterns of Candida species isolated from hospitalized patients in ICUs and NICUs.","volume":"4","author":"Zarei Mahmoudabadi","year":"2015","journal-title":"J Nephropathol"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1345\/aph.1Q346","article-title":"Echinocandin use in the neonatal intensive care unit.","volume":"46","author":"Caudle","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"suppl 2","key":"R17-20230912","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/14767058.2011.604929","article-title":"The management of Candida infections in preterm neonates and the role of micafungin.","volume":"24","author":"Manzoni","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.","volume":"197","author":"Hope","year":"2008","journal-title":"J Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants.","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/clpt.2009.200","article-title":"Safety and pharmacokinetics of repeat-dose micafungin in young infants.","volume":"87","author":"Benjamin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1469-0691.2007.01935.x","article-title":"EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts.","volume":"14","author":"Rodriguez-Tudela","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0b013e31824ab9b0","article-title":"Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.","volume":"31","author":"Undre","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMoa010494","article-title":"Fluconazole prophylaxis against fungal colonization and infection in preterm infants.","volume":"345","author":"Kaufman","year":"2001","journal-title":"N Engl J Med"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"F127","DOI":"10.1136\/fnn.2006.097758","article-title":"Candida parapsilosis infection in very low birthweight infants.","volume":"92","author":"Clerihew","year":"2007","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13052-017-0332-5","article-title":"Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study.","volume":"43","author":"Garzillo","year":"2017","journal-title":"Ital J Pediatr"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/INF.0b013e3182737427","article-title":"Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.","volume":"31","author":"Steinbach","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-014-0725-7","article-title":"Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.","volume":"14","author":"Viscoli","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/QCO.0b013e328337bb42","article-title":"Understanding pharmacokinetics\/pharmacodynamics in managing neonatal sepsis.","volume":"23","author":"Lutsar","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e3181af6201","article-title":"Nephrotoxicity associated with amphotericin B deoxycholate in neonates.","volume":"28","author":"Le","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/14740338.2013.827168","article-title":"Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.","volume":"12","author":"Loo","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","article-title":"Amphotericin B-induced nephrotoxicity: a review.","volume":"12","author":"Fanos","year":"2000","journal-title":"J Chemother"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1128\/AAC.45.10.2845-2855.2001","article-title":"Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1128\/AAC.46.6.1857-1869.2002","article-title":"Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.","volume":"46","author":"Petraitis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis.","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s11255-016-1410-0","article-title":"Micafungin treatment and eradication of candiduria among hospitalized patients.","volume":"48","author":"Gabardi","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.05.010","article-title":"Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.","volume":"48","author":"Grau","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R46-20230912","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1542\/peds.2013-0671","article-title":"Changes in the incidence of candidiasis in neonatal intensive care units.","volume":"133","author":"Aliaga","year":"2014","journal-title":"Pediatrics"},{"key":"R47-20230912","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QCO.0b013e328343614e","article-title":"Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a \u2018right\u2019 choice?","volume":"24","author":"Turkova","year":"2011","journal-title":"Curr Opin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201810000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:15:15Z","timestamp":1694556915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201810000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001996","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}